Therefore, follistatin administration, or other antimyostatin approaches such as decorin, antibodies against myostatin, myostatin propeptide, or shRNA against myostatin [60,64–66] may be investigated as ancillary treatments to improve the effects of MDSC and other stem cell implantation for the treatment of CLI in T2D. The gene discussed is FST; the disease is type 2 diabetes mellitus.